Fort Smith, ARNCT07283939Now EnrollingIRB Ready

Ampulla of Vater Carcinoma Clinical Trial in Fort Smith, AR

Access cutting-edge ampulla of vater carcinoma treatment through this clinical trial at a research site in Fort Smith. Study-provided care at no cost to qualified participants.

Sponsored by Alliance for Clinical Trials in Oncology

Quick Self-Assessment

See if you qualify for this Fort Smith location

Preparing your pre-screening questions…

Expert Care in Fort Smith

Access ampulla of vater carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ampulla of vater carcinoma treatment provided free

Apply for This Fort Smith Location

Check if you qualify for this ampulla of vater carcinoma clinical trial in Fort Smith, AR

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Fort Smith

    Convenient for AR residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Fort Smith site if eligible
  4. 4Begin participation

About This Ampulla of Vater Carcinoma Study in Fort Smith

This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.

Sponsor: Alliance for Clinical Trials in Oncology

Who Can Participate

Inclusion Criteria

REGISTRATION ELIGIBILITY CRITERIA (STEP 1)
Histologic confirmation of invasive cancer that is confirmed or suspected to arise from the gastrointestinal (GI) tract
Any stage for which FOLFOX-based chemotherapy is a clinically-indicated, standard-of-care treatment (adjuvant, neoadjuvant, or first-line chemotherapy)
Eligible primary tumor sites include the esophagus, gastroesophageal junction, stomach, small intestine, ampulla of Vater, appendix, colon, rectum, and cancers of unknown primary with suspected GI origin
Prior systemic therapy for GI cancer (other than cycle 1 of FOLFOX-based chemotherapy) is not allowed. Prior radiation-sensitizing chemotherapy is permitted
The planned duration of FOLFOX-based chemotherapy must be at least four cycles (1 cycle = 14 days)
Cycle 1, day 1 of FOLFOX-based chemotherapy must be completed 1 to 8 days prior to registration
Cycle 1, day 1 of FOLFOX-based chemotherapy must include minimum ordered doses of oxaliplatin (≥ 65 mg/m\^2) and infusional 5-FU (2400 mg/m\^2/46 hours). Use of the 5-FU bolus is at the discretion of the treating physician
Patients who require primary prophylactic white blood cell growth factor with cycle 1 of FOLFOX chemotherapy due to high risk for fever and neutropenia are not eligible
History of hypersensitivity reaction to oxaliplatin or other platinum-based drugs, to fluorouracil, or to leucovorin, and the excipients in their formulations are not eligible
Age ≥ 18 years
ECOG performance status ≤ 2
Absolute neutrophil count (ANC) ≥ 1,000/mm\^3
Platelet count ≥ 100,000/mm\^3
Total bilirubin ≤ 3 x upper limit of normal (ULN)
AST (SGOT)/ALT (SGPT) ≤ 5 x upper limit of normal (ULN)
Calc. creatinine clearance ≥ 30 mL/min
Not pregnant and not nursing, because this study involves agents that have known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done ≤ 30 days prior to registration is required
Patients with treated brain metastases are eligible if follow-up brain imaging after CNS-directed therapy shows no evidence of progression
Patients with known HIV infection are eligible if receiving effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration
Patients with known chronic hepatitis B virus (HBV) infection are eligible if HBV DNA is undetectable when measured within 6 months prior to registration
Patients with a known history of hepatitis C virus (HCV) infection are eligible if HCV RNA is undetectable when measured at least 12 weeks after completion of antiviral therapy
Patients with known history or current symptoms of cardiac disease are eligible if the New York Heart Association Functional Classification is class I or II
Patients with a known history of congenital long QT syndrome are ineligible
Patients with known DPD deficiency are ineligible
NON-PATIENT (ONCOLOGY PHYSICIAN OR ONCOLOGY ADVANCED PRACTICE PROVIDER ELIGIBILITY:
The non-patient provider participant is a medical oncologist or oncology advanced practice provider with responsibility for signing and making necessary modifications to chemotherapy orders for a subject assigned to the intervention arm (Arm B). Non-patient participants may not be enrolled more than once over the course of the study
The non-patient participant must be proficient in the English language
The non-patient participant must be age 21 years or older

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fort Smith?

Yes, this clinical trial (NCT07283939) has an active research site in Fort Smith, AR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Ampulla of Vater Carcinoma Treatment Options in Fort Smith, AR

If you're searching for ampulla of vater carcinoma treatment options in Fort Smith, AR, this clinical trial (NCT07283939) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fort Smith research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ampulla of vater carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Ready to Join in Fort Smith?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Fort Smith, AR